FIELD: oral care.
SUBSTANCE: group of inventions relates to methods and compositions using hydroxyapatite-binding polypeptides (HABP). A method of binding to the enamel and/or dentin surface or targeting the enamel and/or dentin surface of HABP is proposed, comprising applying to the tooth an oral composition containing: а) HABP having a polypeptide sequence according to the formula (I) wherein a, d are independently a hydrophobin or an antifreeze protein sequence or an active ingredient for oral care, b, с independently of each other are an amino acid, y is a polypeptide sequence according to SEQ ID NO: 1 to SEQ ID NO: 16; b) orally acceptable carrier, wherein HABP is present in the composition in an amount from 0.01 wt% up to 3 wt% of the total mass of the composition. Also proposed are: a dental cleaner, an oral care composition for restoring or inhibiting erosion of tooth enamel and a chewing gum composition containing the said HABP; and using the HABP for preparing an oral care composition for restoring or inhibiting dental erosion. A method is proposed for the preparation of an oral care product containing the specified (HABP), including a) neutralization of the HABP solution by diluting with an aqueous buffer solution to obtain a solution having an almost neutral or slightly basic pH value; b) filtering and centrifuging the product solution according to a) producing a HABP-containing filtrate; c) adding fluoride to product filtrate b); d) admixing product c) to the components of an orally acceptable carrier, and an oral composition thus obtained. Also proposed are hydroxyapatite-binding polypeptides, including SEQ ID NO: 1, 2, 3, 4, 6, 8, 16.
EFFECT: НАВР used are effective in restoring or mitigating the effects of dental erosion; they promote dental remineralization and enhance anti-carious effects of fluoride.
17 cl, 1 tbl, 7 ex
Title | Year | Author | Number |
---|---|---|---|
ORAL CARE PRODUCTS AND METHODS CONTAINING HLP | 2016 |
|
RU2759134C2 |
GLYCOSYLATED FUSED PROTEINS VWF WITH IMPROVED PHARMACOKINETICS | 2017 |
|
RU2782212C2 |
RECOVERED NUCLEIC ACID WHICH CODES FVIII-BDD-BASED FUSION PROTEIN AND HETEROLOGOUS SIGNAL PEPTIDE, AND USE THEREOF | 2022 |
|
RU2818229C2 |
GENE THERAPY OF HYPOPHOSPHATEMIC DISEASES ASSOCIATED WITH FIBROBLAST GROWTH FACTOR 23 | 2020 |
|
RU2815545C2 |
COMPOSITION FOR PREVENTION AND TREATMENT OF SKIN DISEASE CONTAINING SUBSTANCE SPECIFICALLY BINDING WITH VIMENTINE DERIVATIVE PEPTIDE | 2018 |
|
RU2751486C1 |
PREPARATION CONTAINING VIII FACTOR AND VON WILLEBRAND FACTOR PEPTIDES | 2015 |
|
RU2714154C2 |
COMPOSITIONS AND METHODS FOR DEGRADATION OF IMPROPERLY PACKAGED PROTEINS | 2016 |
|
RU2761564C2 |
FUSED MOLECULES DERIVED FROM CHOLIX-TOXIN FOR ORAL DELIVERY OF BIOLOGICALLY ACTIVE LOADS | 2015 |
|
RU2723178C2 |
STABILIZED F RSV PROTEINS AND THEIR USE | 2019 |
|
RU2795459C2 |
LACTASE ENZYMES WITH IMPROVED PROPERTIES | 2018 |
|
RU2788608C2 |
Authors
Dates
2021-04-05—Published
2016-10-25—Filed